

Mark Garofoli, PharmD, MBA, BCGP, CPE SEMPP Director

November 2017



Vision


Improve lives of patients experiencing chronic pain, while aiming to save lives as well.

Mission

Transform the "Best Practices" of Pain Management into the new "Standard of Care".

General Description

The Safe & Effective Management of Pain Program (SEMPP) is a coordinated care program for patients on chronic opioid therapy. SEMPP was developed for West Virginia healthcare insurers, while having foundational support via a CDC Prescription Drug Overdose (PDO) Prevention for States (PfS) Grant in conjunction with the WV Department of Health & Human Resources.



SEMPP[®] Prior Authorization (PA) Form

Laboratory Findings (Please attach and/or describe)

					-		
				Please describe any MRI, X-Ray, or Ultrasound (Radiology) results relevant to the pain management			
MEDICAL INFORMATION Please attach or list patient's current complete medication list with the medical condition being treated included for each medication. (Prescriptions, Non-Prescriptions, Failed pain medications, Supplements, Herbals,& Illicit Substances) <u>Current medications</u> <u>Previously failed pain medications</u>		ıded					
			Has the patient experienced a decrease in his/her d complete house work, perform tasks, etc.) beyond a	aily function (i.e. ability to climb stairs, subjective increase in daily pain?	🗆 Yes	🗆 No	
				Has the patient been screened for risk of opioid-use (Indicate by which risk screening tool) Opioid Risk Tool (ORT)	disorder?	🗆 Yes	🗆 No
				 Current Opioid Misuse Measure (COMM) Prescription Drug Use Questionnaire (PDUQ) 	 Diagnosis, Intractability, Risk, & Efficacy Pain Medication Questionnaire (PMQ) 	Score (D	IRE)
Is the patient pregnant?		🗆 Yes 🗆 N	No				
Is the patient allergic to any opioid medications (If yes, please list and describe reactions in 2 to 3 words)?		No	Has a current and up-to-date Patient & Provider(s) attached? (Including a review of reasonable therapy function, and a stated end of therapy time frame)	Agreement/Contract been signed and goals of reducing pain, improving daily	🗆 Yes	🗆 No	
Does the patient have impaired renal function (If yes, please provide GFR/CrCl)?		No	Has the patient been educated on proper medication to controlled substances?	n storage and disposal, with special regard	🗆 Yes	🗆 No	
Does the patient have impaired hepatic function (If yes, please provide LFTs)?		🗆 Yes 🗖 N	No	Based on the patient's 90-day cumulative daily aver has the patient been educated on being a candidate	age morphine milligram equivalent dose, for carrying naloxone?	🗆 Yes	□ No
Physical exam findings relevant to pain management				Has the patient been prescribed naloxone?		🗆 Yes	🗆 No
				Monitoring the Prescription Drug Monitoring Pr Controlled Substance Monitoring Program (CSMP reviewed immediately prior to the prescribing of t discrepancies existed, attached to this request? (The with the WV PDMP administration)), is required by law. Has the PDMP been he requested opioid medication and, if any	□ Yes	□ No
				Has a Urine Drug Screening/Test been completed p opioid medication (Please attach or provide results)		🗆 Yes	🗆 No

Proactive Responses from Prescriber's Offices Examples of Documentation Provided

PDMP documentation provided

• Examples from WV, VA, & MD

Pharmacogenetic Testing Results

Opioid Response Testing & CYP Enzyme Activity Testing

Urine Drug Testing Results (Screening Examples Descriptions also)

Chart Notes

- "Patient doesn't want an increase in overall opioid dosage due to insurance prior authorization being needed."
 - Example of patient knowing insurance provider is looking out for their safety.

Observational Responses from Prescriber's Offices Examples of Documentation Provided

Prescriber Statements (Situation)	Prescriber's Request					
Chart Notes						
"Patient reports occasional marijuana use"	Opioid medication continuation.					
"Patient was without opioid medication last month"	Opioid medication to be reinitiated at previous high risk dosage.					
"Real patients, real problems"	"If insurer won't pay for pain meds, patient will pay cash."					
UDS						
UDS positive for non-prescribed benzodiazepine & THC.	770 MEDD requested to be continued (methadone 10mg 5/Day & oxycodone IR 30mg 6/Day)					
PA Form						
"Patient known addict" & "Patient had oxycodone and clonazepam from a family member".	Opioid continuation despite lack of PDMP review.					
"Known patient for 20 years", has a "verbal contract", & "patient not at risk" (even though > 50 MME/Day).	Opioid continuation despite lack of opioid risk screening, signed agreement/contract, & lack of patient naloxone education.					


Concerning Responses from Prescriber's Offices Examples of Documentation Provided

Prescriber Statements (Situation)	Prescriber's Request				
Chart Notes					
"Patient charged with heroin distribution", & "UDS shows no oxycodone metabolites"	Oxycodone continuation.				
<u>PA Form</u>					
Opinionated response with profanities, and a statement that "PDMP was not around in 2013 (i.e. initial prescribing), but checked a few months ago".	Opioid medication continuation.				
Response Letter to original notification letter					
Patient was receiving 1,000 oxycodone IR 30mg tablets monthly (1,560 MME/Day).	Prescriber stated gradually tapering down to 630 tablets monthly (945 MME/Day).				
	 Months later, rejected claims for 720 tablets monthly continue to appear (1,080 MME/Day) 				
	Another patient at same address, rejected claims for 120 tablets monthly continue to appear (180 MME/Day) despite SEMPP denial of 240 tablets monthly.				

Concerning Responses from Prescriber's Offices Examples of Documentation Provided

Prescriber Statements (Situation)	Response					
Phone Calls						
 Specialty pharmacy requests dosage increase of morphine 50mg/mL: ➢ From 7ml/Day to 15mL/Hour. ➢ MEDD increase from 1,250 to 18,900 	Instructed to call the prescriber immediately.					
 Prescriber of multiple high risk opioid dosage patients (hundreds of MME/Day) refused to educate patients on naloxone. > Cited "1994 & 1996 JAMA articles stated that naloxone causes nausea and vomiting". 	After multiple conversations, prescriber eventually agreed to educate patients on naloxone, but not prescribe it.					
 Appeal a "dosage increase denial" for increased oxycodone ER dosage from 4/Day to 10/Day (+oxycodone IR 30mg 12/Day) ➢ Increase 1,020 MEDD to 1,740 MEDD ➢ Discussed safety and minimum need to review the PDMP. 	Prescriber responded, "What is a PDMP?"					

Enriched Patient Case Authorization Reviews More than just pain management...



SEMPP Metrics


November 2017

Top 10 Opioids Prescribed by Substance

Most common drug OXYCODONE 1213 1 MORPHINE 463 2 3 FENTANYL 324 171 METHADONE 4 155 5 OXYMORPHONE HYDROCODONE 101 6 HYDROMORPHONE 42 7 30 8 TAPENTADOL 9 TRAMADOL 10 PENTAZOCINE 5 10

Most common Rx						
1	OXYCODONE/APAP TABLET	10MG- 325MG	298			
2	OXYCODONE IR	15 MG	220			
3	OXYCODONE IR	30 MG	209			
4	MORPHINE SULF ER TABLET	30 MG	161			
5	METHADONE	10 MG	159			
6	OXYCODONE IR	10 MG	147			
7	OXYCODONE IR	20 MG	138			
8	MORPHINE SULF ER TABLET	15 MG	96			
9	FENTANYL PATCH	50MCG/HR	89			
10	FENTANYL PATCH	25MCG/HR	83			


Top 10 Opioids Prescribed by Product




Geographical Location of Prescribers

SEMPP[®] WV Medicaid Metrics

November 2017







Questions & Discussion



